Hospital ‘Xpovio’s benefit expected in DLBCL patients with brain metastasis’ After CAR-T cell therapy Kymriah (tisagenlecleucel) became reimbursable in April, Korean doctors are shifting the treatment focus to CAR-T cell therapy to treat relapsed/refracto

Media coverage

• Title	Hospital ‘Xpovio’s benefit expected in DLBCL patients with brain metastasis’ After CAR-T cell therapy Kymriah (tisagenlecleucel) became reimbursable in April, Korean doctors are shifting the treatment focus to CAR-T cell therapy to treat relapsed/refracto
  Media name/outlet	Korea Biomedical Review
  Date	25/05/22
  URL	www.koreabiomed.com/news/articleView.html?idxno=13757
  Persons	Young Sup Woo